Recent Updates
Recently added Catalysts

Prostate Cancer: 6 biotech companies competing in the clinic

OncologyKnife fightData as of 2026-09-04

Competitors6in the clinic
Median market cap$1.1Buniverse median $1.20B
Allocated capital$2.7B$13.5B competing
Phase 3 or filed11 mid, 4 early
Pure plays0this indication only
Capital rank74/299crowding rank 29

Prostate Cancer is one of the more crowded fields on the map: 6 companies in the clinic, ranking it 29th of 299 indications by competitor count. The median competitor is worth $1.1B, below the $1.20B median of the universe.

That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.

IBRX carries 64% of the $13.5B competing here, more than the other 5 companies combined.

$2.7B of allocated capital sits in Prostate Cancer, ranking it 74th of 299 indications by the money committed to it.

Companies developing drugs for Prostate Cancer 6

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CADLCandel Therapeuticsaglatimagene besadenovecPhase 34$992MNo2 30 Sep 2026
DSGNDesign TherapeuticsAbiraterone- UsualPhase 22$941MNo6 31 Dec 2026
IBRXImmunityBioN-803Phase 11$8.7BNo12 31 Dec 2026
ORICOric PharmaceuticalsORIC-944Phase 13$1.3BNo2 1 Oct 2026
JANXJanux TherapeuticsJANX007Phase 13$1.2BNo2 31 Dec 2026
AGENAgenusBalstilimabPhase 13$371MNo7 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. IBRX holds 64% of the $13.5B competing in this indication.

Why Prostate Cancer is a knife fight

Crowded and cheaply priced. Six or more competitors and a median company below the universe median.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Prostate Cancer has 6 competitors and a median of $1.1B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Breast Cancer10 companies · $2.7B · median $288MKnife fightNon-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontestedMetastatic Castration Resistant Prostate Cancer3 companies · $2.8B · median $4.0BConcentrated betMeningioma3 companies · $2.5B · median $14.7BConcentrated betGlioblastoma6 companies · $3.0B · median $432MKnife fightChronic Myelogenous Leukemia2 companies · $2.4B · median $3.0BConcentrated betPancreatic Cancer9 companies · $2.4B · median $371MKnife fightMelanoma4 companies · $2.3B · median $2.6BConcentrated bet

Prostate Cancer pipeline questions

Which biotech companies are developing drugs for Prostate Cancer?

6 US-listed companies in the $100M to $20B market cap band run clinical programmes in Prostate Cancer. The largest and most advanced are Candel Therapeutics (CADL, aglatimagene besadenovec, Phase 3); Design Therapeutics (DSGN, Abiraterone- Usual, Phase 2); ImmunityBio (IBRX, N-803, Phase 1); Oric Pharmaceuticals (ORIC, ORIC-944, Phase 1); Janux Therapeutics (JANX, JANX007, Phase 1). The full list of 6 is in the table on this page.

How advanced is the Prostate Cancer pipeline?

Of the 6 clinical-stage programmes in Prostate Cancer, 1 is in Phase 3 or filed, 1 is in mid-stage development and 4 are in early-stage development.

Which company leads the Prostate Cancer field?

IBRX is the largest developer in Prostate Cancer, holding 64% of the $13.5B of market capitalisation competing in the indication. The median competitor is worth $1.1B.

When is the next Prostate Cancer catalyst?

The next dated catalyst in Prostate Cancer is CADL on 30 Sep 2026. 6 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map